P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS
Bruno Paiva,
Bonny Gaffney,
Kelven Burnett,
Paola Castiglioni,
Michael Angelo,
Daniel W. Pierce,
Isaac Boss
Affiliations
Bruno Paiva
1 Clinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigación Medica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
Bonny Gaffney
2 Bristol Myers Squibb, San Diego, United States
Kelven Burnett
2 Bristol Myers Squibb, San Diego, United States
Paola Castiglioni
2 Bristol Myers Squibb, San Diego, United States
Michael Angelo
2 Bristol Myers Squibb, San Diego, United States
Daniel W. Pierce
3 Bristol Myers Squibb, San Francisco, United States
